- Company
- Different progress of three new asthma drugs launched
- by Eo, Yun-Ho Sep 11, 2023 05:29am
- The results of the three types of asthma antibody drugs were different. According to the related industry, at the HIRA Pharmaceutical Reimbursement Evaluation Committee held on the 7th, Nucala of GSK Korea was judged to be appropriate for reimbursement, and Fasenra of AstraZeneca Korea was judged to be non-reimbursable. These drugs are in
- Company
- Rebamipide survives reimb evaluations...a relief
- by Chon, Seung-Hyun Sep 11, 2023 05:29am
- The gastric ulcer treatment ‘rebamipide’ survived Korea’s reimbursement reevaluations. As a result, pharmaceutical companies were able to hold on to their cash cow that brings in KRW 140 billion per year. The Health Insurance Review and Assessment Service concluded that the active substance rebamipide was adequate for reimbursement after d
- Opinion
- [Reporter's view] Obesity-themed stocks
- by Lee, Seok-Jun Sep 11, 2023 05:29am
- The theme stock craze is happening again. This time it is related to obesity treatment. Companies that ride on theme stocks easily hit the upper price limit. There is also a bio venture that recorded the upper limit three times, ‘up, up, up’ on the full moon. It is easy to find companies whose market capitalization has doubled in just a fe
- Company
- 2nd-gen CML drug approved for reimb following 4th-gen drug
- by Eo, Yun-Ho Sep 11, 2023 05:29am
- Companies are actively working to expand insurance coverage for their prescription chronic myeloid leukemia treatments in Korea. According to the industry sources, Novartis Korea's 4th generation CML treatment ‘Scemblix (asciminib)' was listed for reimbursement last July, and Pfizer Korea's 2nd generation drug 'Bosulif (bosutinib)' also
- Company
- The generic for exclusivity period for Vemlidy ends
- by Kim, Jin-Gu Sep 8, 2023 05:34am
- The generic exclusivity period for the hepatitis B treatment Vemlidy expires on the 15th of this month. Five additional companies that have received approval for generic drugs for this ingredient are expected to enter the market. The pharmaceutical industry is paying attention to whether the original will have an impact on the market share,
- Policy
- Next year's new drug R&D budget: 58 billion won
- by Lee, Jeong-Hwan Sep 8, 2023 05:34am
- The Ministry of Health and Welfare has set the national new drug development (R&D) budget for next year (2024) to 57.99 billion won, an increase of about 16.1 billion won from this year's budget of 41.19 billion won. 10.4 billion won was allocated to research to expand the new drug base, 16.5 billion won to research to build a new drug R&D e
- Product
- Phentermine and Saxenda has most reported adverse events
- by Lee, Jeong-Hwan Sep 8, 2023 05:33am
- Phentermine, a psychotropic appetite suppressant, was found to have the highest number of reported adverse events among anti-obesity drugs prescribed in Korea. Saxenda, an anti-obesity drug that was developed by changing the MOA of a diabetes drug, had the second-most reported number of side effects after phentermine. On the 7th, the
- Company
- Appearance of 3rd generation MAO-B inhibitors
- by Eo, Yun-Ho Sep 8, 2023 05:33am
- Parkinson's disease is one of the diseases for which treatment development is slow. It is known that a cure is still impossible, and treatment focuses on suppressing the progression of the disease or alleviating symptoms. Madopar, a representative treatment, is the drug with the greatest anti-Parkinson effect and has become the gold standard
- Policy
- Advanced biologics to receive expedited review
- by Lee, Hye-Kyung Sep 8, 2023 05:33am
- Advanced biological drugs that have demonstrated a significant improvement in safety or effect compared to existing treatments will be regarded as ‘drugs with no alternatives’ and allowed to receive expedited review in Korea. Until now, only advanced biopharmaceuticals with limited scope of application (such as patients who have posit
- Policy
- Yooyoung will newly release repackaged flagship Pravafenix
- by Lee, Tak-Sun Sep 7, 2023 03:50pm
- Yooyoung Pharmaceutical has voluntarily withdrawn the marketing authorization for its product, ‘Pravafenix Cap’, as the product is due for a packaging renewal. As a flagship product, Pravefenix Cap has been recording annual sales of approximately 20 billion KRW. The newly self-packaged product is expected to be listed for reimbursement
